rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Jupiter Neurosciences, Inc.

JUNS · Nasdaq

Health CareBiotechnologyNot moving yetNeurotech

JUNS stood above a rising 150-day average in 4 of the last 52 weekly readings, and has been out of that trend for the last 48 weeks. It is 80.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 48
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
12 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 4 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$9,488Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders12+4 on the quarter
New · exited6 · 3
Reported value$220K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
JANE STREET GROUP, LLCnew · filed 14 Aug 2026533,395$114K+533,395
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026156,127$33K-55,569−26.2%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026128,042$27K-231,869−64.4%
VANGUARD FIDUCIARY TRUST COreduced · filed 13 Aug 202684,173$18K-3,616−4.1%
XTX Topco Ltdnew · filed 14 Aug 202632,770$7,019+32,770
Tower Research Capital LLC (TRC)new · filed 11 Aug 202628,786$6,166+28,786
NORTHERN TRUST CORPunchanged · filed 13 Aug 202625,346$5,42900.0%
StoneX Group Inc.new · filed 12 Aug 202620,602$5,678+20,602
LEVEL FOUR ADVISORY SERVICES, LLCnew · filed 10 Aug 202610,000$2,142+10,000
MidFirst Bankunchanged · filed 7 Aug 20261,000$21400.0%
31 Dec 2024 – 30 Jun 2026
2712Dec 24Jun 25Sep 25Mar 26Jun 26

Everyone who traded it

Andrew Jon Cutler Company insiderDirector · last 31 Jul 20260 · 0
Tomas Jan Philipson Company insiderDirector · last 29 Jun 20260 · 0
Alexander Gustaf Erik Rosen Company insiderChief Administrative Officer · last 2 Jun 20260 · 0
Alison D. Silva Company insiderPresident and COO · last 2 Jun 20263 · 0
Allison W. Brady Company insiderDirector · last 2 Jun 20260 · 0
Christer Rosen Company insiderCEO and Chairman · last 2 Jun 20263 · 0
Holger Weis Company insiderDirector · last 2 Jun 20260 · 0
Julie B. Kampf Company insiderDirector · last 2 Jun 20260 · 0
Marshall A. Hayward Company insiderChief Scientific Officer · last 2 Jun 20260 · 0
Nicholas H. Hemmerly Company insiderDirector · last 2 Jun 20260 · 0
Saleem Elmasri Company insiderChief Financial Officer · last 2 Jun 20260 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202580.6%
Share count trendFY 2025 · to 31 Mar 20265.3%

Analyst forecasts

No analyst forecasts yet.